On October 6, 2023, the Drug Enforcement Agency (DEA) and the Department of Health and Human Services (HHS) made the noteworthy decision to extend COVID-19 flexibilities, permitting prescription of controlled substances through telemedicine without the need for a preceding in-person evaluation. This temporary rule is now in effect until December 31, 2024. The implications of this Second Temporary Rule and key points for relevant providers and entities are worth considering.
This change has followed the growing acceptance and utilization of telemedicine during the COVID-19 pandemic, which has compelled the DEA and HHS to reevaluate their policies regarding controlled substances prescription via this medium. Under the previous rules, physicians were required to first conduct an in-person medical evaluation before turning to the telemedicine option, obviously a challenge amidst the ongoing global health crisis.
To shed light on the context of this ruling, it was initially introduced as a reaction to the pandemic’s early stages when the need for remote prescription was stark and immediate. Following the same, the extension to current times reflects the persistent health concerns and continued societal preference for remote services.
From a legal standpoint, the extension of the temporary rule opens up a host of questions for the future. Four key takeaways should be noted. First, practitioners who prescribe controlled substances via telemedicine must hold appropriate registrations. Second, the telemedicine communication technology must be compliant with the requirements of the Ryan Haight Act. Third, this privilege applies only to the telemedicine prescription of controlled substances for legitimate medical purposes. Finally, the extended rule applies to every other condition, not just COVID-19, creating broader scope.
While these are only temporary regulations, their vast implications should draw the attention of all legal professionals in the healthcare sector, as well as business entities and individual practitioners. The entire regulatory landscape surrounding controlled substances and telemedicine might witness a significant evolution as the aftermath of these extensions unfolds over the next two years.
For the complete details of the mandate, visit the link: Baker Donelson article via JD Supra.